Abstract : Dyspepsia consists of heterogeneous group of symptoms that are localized in the epigastric region and can be broadly defined as pain or discomfort that is centred in the upper abdomen (particularly the epigastrium). The multienzyme preparation “Unienzyme” is a fixed dose combination (FDC) which contains Fungal Diastase (alpha amylase) and Papain as the major constituents apart from simethicone, activated charcoal and nicotinamide. The combination acts as supplemental enzymes to those secreted by the body. Since majority of patients require long term symptomatic treatment for functional dyspepsia, we undertook a survey to evaluate the efficacy, tolerability as well as other parameters such as duration of treatment, time to get relief from symptoms etc. The survey was conducted between July 2023 to October 2023 in Africa specifically in Tanzania and Zambia. The questionnaire was developed for doctors who were prescribing Unienzyme with MPS to their patients for gastrointestinal disorders and who consented to participate in the survey. A total of 105 doctors participated in this survey. Findings about efficacy and tolerability also coincides with the study conducted by Banka et al (8), while the 95.6% patients in their study and 86.66% doctors in our study rated the efficacy from good to excellent. 94.5% patients in previous study and 84% doctors in this study rated the tolerability of Unienzyme as very good to excellent. The difference could be attributed to clinician’s judgement in our study as compared to patients’s judgement in previous study. The present survey confirmed that Unienzyme is highly efficacious with good tolerability in relieving the symptoms of troublesome functional dyspepsia in African population especially Tanzania, Zambia and neigbouring countries.